Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

Verona Pharma reported a total of $36 million in net revenue for the fourth quarter of 2024, solely attributed to sales of Ohtuvayre (ensifentrine), its FDA-approved treatment for chronic ...

And I predict that 2025 will be another momentous year for Summit. Summit already owned the license to market ivonescimab in ...

For further information please contact: Verona P Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique ...

Verona Pharma reported a total of $36 million in net revenue for the fourth quarter of 2024, solely attributed to sales of Ohtuvayre (ensifentrine), its FDA-approved treatment for chronic obstructive ...

and now Verona has revealed the drug made approximately $36 million in the final three months of 2024, off more than 16,000 prescriptions. Chief executive David Zaccardelli said Ohtuvayre was off ...

Discover the top-performing biotech stocks in 2024! From oncology to psychedelics some companies showed remarkable results.